Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of Monopar Therapeutics
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001645469.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
6/50
Latest evidence
02 Nov 2026
- Public ticker
- MNPR on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Nov 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001645469
- Issuer location
- Wilmette, IL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Monopar Therapeutics (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
6/50
Latest evidence
02 Nov 2026
13D/G
13F
3/4/5
Lead comparable stake: 20%
44 rows are not safely comparable across share classes.
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 20%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
20%
RA CAPITAL MANAGEMENT, L.P.
9.9%
ASTRAZENECA PLC
7.8%
BlackRock, Inc.
5%
Adage Capital Management, L.P.
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
20%
Reported 13D/G
· 30 Sep 2025
|
$105,138,701
1,287,368 shares
|
+$9,391,992 | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
9.9%
Reported 13D/G
· 31 Dec 2025
|
$61,776,696
667,207 shares
|
— | 30 Jun 2026 |
| ASTRAZENECA PLC |
13D/G
|
7.8%
Reported 13D/G
· 31 Dec 2025
|
$34,126,392
522,667 shares
|
$0 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
Reported 13D/G
· 30 Sep 2026
|
$32,297,151
348,819 shares
|
— | 30 Jun 2026 |
| Adage Capital Management, L.P. |
13D/G
|
4.8%
Reported 13D/G
· 30 Jun 2026
|
$31,485,818
324,195 shares
|
-$9,712,000 | 30 Jun 2026 |
| Saturn V Capital Management LP |
13D/G
13F
Company
|
4.7%
Reported 13D/G
· 30 Jun 2026
|
$30,435,854
313,384 shares
|
-$3,131,343 | 30 Jun 2026 |
| Hendricks Diane |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$50,213,802
567,580 shares
|
— | 16 Dec 2025 |
| Tactic Pharma LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$17,303,519
272,026 shares
|
— | 24 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$4,767,523.
Buys
$104,925
Insiders: 1
Sells
$4,872,448
Insiders: 6
Net
-$4,767,523
Shares: -55,542
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,500
Shares: 57,042
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 51,921 | $0 | $4,528,559 | -$4,528,559 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 1,500 | 5,121 | $104,925 | $343,889 | -$238,964 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Monopar Therapeutics. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Hendricks Diane
Net 12M change
-$4.77M
Full value: -$4,767,523 · USD · 12-month changeLatest report
02 Nov 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Hendricks Diane | 10%+ Owner | $50,213,802 | Mixed | 16 Dec 2025 | ||
| Tactic Pharma LLC | 10%+ Owner | $17,303,519 | Filing P/S | 24 Sep 2025 | ||
| Chandler Robinson | Chief Executive Officer, Director | $16,746,615 | -$2,556,851 | -13% | Mixed | 20 Oct 2026 |
| Andrew Cittadine | Chief Operating Officer | $6,511,629 | Mixed | 30 Sep 2026 | ||
| Christopher M. Starr | Director | $1,326,921 | -$659,387 | -33% | Mixed | 01 Oct 2026 |
| Kim R. Tsuchimoto | Director | $915,088 | -$745,628 | -45% | Median | 02 Nov 2026 |
| Arthur J. Klausner | Director | $596,604 | -$343,889 | -37% | Filing P/S | 18 Dec 2025 |
| Patrice Rioux | Acting Chief Medical Officer | $563,531 | -$111 | -0.02% | Filing P/S | 26 Aug 2026 |
| Raymond Anderson | Director | $376,324 | -$566,582 | -60% | Filing P/S | 02 Nov 2026 |
| Lavina Talukdar | Director | $308,022 | Mixed | 02 Dec 2025 | ||
| Quan Anh Vu | Chief Financial Officer | $245,826 | +$104,925 | +74% | Mixed | 30 Sep 2026 |
| Michael J. Brown | Director | $136,941 | Mixed | 31 Dec 2023 | ||
| Andrew Paul Mazar | Chief Scientific Officer, Director | $94,434 | Mixed | 31 Mar 2022 | ||
| Karthik Radhakrishnan | Chief Financial Officer | $10,447 | Mixed | 28 Oct 2024 | ||
| TacticGem LLC | 10%+ Owner | $0 | Mixed | 09 Dec 2024 | ||
| Nicole Sweeny | Director | Mixed | 26 Jun 2026 | |||
| Susan Rodriguez | Ccso | Mixed | 02 Mar 2026 | |||
| Jose Octavio Pinto Costa Filho | Chief Medical Officer | Mixed | 12 Jul 2021 |
Recent insider transactions for Monopar Therapeutics
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim R. Tsuchimoto | MNPR | Common Stock | Sale | -100% | -$206,012 | $71.26 | -2,891 | 0 | 04 Nov 2026 | Direct |
| Kim R. Tsuchimoto | MNPR | Common Stock | Options Exercise | 2,891 | 2,891 | 04 Nov 2026 | Direct | |||
| Kim R. Tsuchimoto | MNPR | Stock Option | Options Exercise | -41.3% | -2,891 | 4,110 | 04 Nov 2026 | Direct | ||
| Raymond Anderson | MNPR | Common Stock | Sale | -36.9% | -$214,746 | $68.35 | -3,142 | 5,373 | 02 Nov 2026 | Direct |
| Raymond Anderson | MNPR | Common Stock | Options Exercise | 58.5% | 3,142 | 8,515 | 02 Nov 2026 | Direct | ||
| Raymond Anderson | MNPR | Stock Option | Options Exercise | -69.2% | -3,142 | 1,401 | 02 Nov 2026 | Direct | ||
| Kim R. Tsuchimoto | MNPR | Common Stock | Sale | -100% | -$84,050 | $70.10 | -1,199 | 0 | 02 Nov 2026 | Direct |
| Kim R. Tsuchimoto | MNPR | Common Stock | Options Exercise | 1,199 | 1,199 | 02 Nov 2026 | Direct | |||
| Kim R. Tsuchimoto | MNPR | Stock Option | Options Exercise | -19.4% | -1,199 | 4,966 | 02 Nov 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -0.57% | -597 | 104,127 | 20 Oct 2026 | Direct | ||
| Christopher M. Starr | MNPR | Common Stock | Sale | -61.9% | -$659,387 | $78.50 | -8,400 | 5,173 | 01 Oct 2026 | Direct |
| Christopher M. Starr | MNPR | Common Stock | Options Exercise | 162.4% | 8,400 | 13,573 | 01 Oct 2026 | Direct | ||
| Christopher M. Starr | MNPR | Stock Option | Options Exercise | -50% | -8,400 | 8,400 | 01 Oct 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -3.24% | -1,944 | 58,054 | 30 Sep 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 7.88% | 4,384 | 59,998 | 30 Sep 2026 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Unit | Options Exercise | -11.1% | -4,384 | 35,115 | 30 Sep 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -3.98% | -4,344 | 104,724 | 30 Sep 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 9.87% | 9,801 | 109,068 | 30 Sep 2026 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Unit | Options Exercise | -10.5% | -9,801 | 83,602 | 30 Sep 2026 | Direct | ||
| Quan Anh Vu | MNPR | Common Stock | Tax liability | -6.35% | -180 | 2,655 | 30 Sep 2026 | Direct | ||
| Quan Anh Vu | MNPR | Common Stock | Options Exercise | 27.6% | 614 | 2,835 | 30 Sep 2026 | Direct | ||
| Quan Anh Vu | MNPR | Restricted Stock Unit | Options Exercise | -7.14% | -614 | 7,984 | 30 Sep 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Sale | -22.6% | -$2,556,851 | $88.00 | -29,056 | 99,267 | 24 Sep 2026 | Direct |
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 29.3% | 29,056 | 128,323 | 24 Sep 2026 | Direct | ||
| Chandler Robinson | MNPR | Stock Option | Options Exercise | -65.9% | -29,056 | 15,044 | 24 Sep 2026 | Direct | ||
| Kim R. Tsuchimoto | MNPR | Common Stock | Sale | -100% | -$455,567 | $111.39 | -4,090 | 0 | 26 Aug 2026 | Direct |
| Kim R. Tsuchimoto | MNPR | Common Stock | Options Exercise | 4,090 | 4,090 | 26 Aug 2026 | Direct | |||
| Kim R. Tsuchimoto | MNPR | Stock Option | Options Exercise | 101% | 4,090 | 8,140 | 26 Aug 2026 | Direct | ||
| Patrice Rioux | MNPR | Common Stock | Sale | -0.02% | -$111 | $111.26 | -1 | 5,065 | 26 Aug 2026 | Direct |
| Patrice Rioux | MNPR | Common Stock | Options Exercise | 37.4% | 1,380 | 5,066 | 26 Aug 2026 | Direct | ||
| Patrice Rioux | MNPR | Stock Option | Options Exercise | 1,380 | 0 | 26 Aug 2026 | Direct | |||
| Raymond Anderson | MNPR | Common Stock | Sale | -36.9% | -$351,835 | $111.98 | -3,142 | 5,373 | 25 Aug 2026 | Direct |
| Raymond Anderson | MNPR | Common Stock | Options Exercise | 58.5% | 3,142 | 8,515 | 25 Aug 2026 | Direct | ||
| Raymond Anderson | MNPR | Stock Option | Options Exercise | 929.6% | 3,142 | 3,480 | 25 Aug 2026 | Direct | ||
| Quan Anh Vu | MNPR | Common Stock | Tax liability | -18.6% | -507 | 2,221 | 30 Jun 2026 | Direct | ||
| Quan Anh Vu | MNPR | Common Stock | Options Exercise | 81.9% | 1,228 | 2,728 | 30 Jun 2026 | Direct | ||
| Quan Anh Vu | MNPR | Restricted Stock Unit | Options Exercise | -12.5% | -1,228 | 8,598 | 30 Jun 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -3.95% | -4,084 | 99,267 | 30 Jun 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 14.2% | 12,873 | 103,351 | 30 Jun 2026 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Unit | Options Exercise | -12.1% | -12,873 | 93,403 | 30 Jun 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -3.99% | -2,309 | 55,614 | 30 Jun 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 9.98% | 5,254 | 57,923 | 30 Jun 2026 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Unit | Options Exercise | -11.7% | -5,254 | 39,499 | 30 Jun 2026 | Direct | ||
| Nicole Sweeny | MNPR | Stock Options | Award | 1,284 | 1,284 | 26 Jun 2026 | Direct | |||
| Chandler Robinson | MNPR | Common Stock | Tax liability | -2.13% | -1,972 | 90,478 | 31 Mar 2026 | Direct | ||
| Chandler Robinson | MNPR | Common Stock | Options Exercise | 7.85% | 6,732 | 92,450 | 31 Mar 2026 | Direct | ||
| Chandler Robinson | MNPR | Restricted Stock Unit | Options Exercise | -5.96% | -6,732 | 106,276 | 31 Mar 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Tax liability | -2.9% | -1,571 | 52,669 | 31 Mar 2026 | Direct | ||
| Andrew Cittadine | MNPR | Common Stock | Options Exercise | 6.93% | 3,514 | 54,240 | 31 Mar 2026 | Direct | ||
| Andrew Cittadine | MNPR | Restricted Stock Unit | Options Exercise | -7.28% | -3,514 | 44,753 | 31 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.